Our study explores one such robot – the Revo-i (Meerecompany, Seongnam, Republic of Korea). Although from a research point of view, a 33-patient sample is a small number, this is the largest study done on this novel robotic system, and one of the biggest preliminary studies for a new robotic system. We explore short-term oncologic outcomes in this study and expect longer-term outcomes in studies to come. A matched prostate cancer cohort serves as the matched control; we have published along with it a supplementary table, which accompanies the full text of the article, in which the Revo-i cohort is compared to an 1121 single surgeon Retzius-sparing robot prostatectomy cohort.
Written by: Sylvia Alip, MD, University of the Philippines-Philippine General Hospital Department of Surgery, Urology, Manila, Philippines
Read the Abstract